ID26790A - Penghambat sinthase nitrat oksida - Google Patents

Penghambat sinthase nitrat oksida

Info

Publication number
ID26790A
ID26790A IDW20002495A ID20002495A ID26790A ID 26790 A ID26790 A ID 26790A ID W20002495 A IDW20002495 A ID W20002495A ID 20002495 A ID20002495 A ID 20002495A ID 26790 A ID26790 A ID 26790A
Authority
ID
Indonesia
Prior art keywords
oxida
obstacles
synthase
nitrate
nitrate synthase
Prior art date
Application number
IDW20002495A
Other languages
English (en)
Indonesian (id)
Inventor
Paul John Beswick
Savas Kleanthous
Robert John Young
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of ID26790A publication Critical patent/ID26790A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IDW20002495A 1998-05-30 1999-05-27 Penghambat sinthase nitrat oksida ID26790A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9811599.1A GB9811599D0 (en) 1998-05-30 1998-05-30 Nitric oxide synthase inhibitors

Publications (1)

Publication Number Publication Date
ID26790A true ID26790A (id) 2001-02-08

Family

ID=10832929

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20002495A ID26790A (id) 1998-05-30 1999-05-27 Penghambat sinthase nitrat oksida

Country Status (31)

Country Link
US (2) US6355689B1 (hu)
EP (1) EP1084104B1 (hu)
JP (1) JP3839256B2 (hu)
KR (1) KR20010043920A (hu)
CN (1) CN1218940C (hu)
AP (1) AP1382A (hu)
AT (1) ATE245142T1 (hu)
AU (1) AU757042B2 (hu)
BR (1) BR9910849A (hu)
CA (1) CA2333322C (hu)
CZ (1) CZ297473B6 (hu)
DE (1) DE69909625T2 (hu)
DK (1) DK1084104T3 (hu)
EA (1) EA003026B1 (hu)
EE (1) EE04149B1 (hu)
ES (1) ES2203147T3 (hu)
GB (1) GB9811599D0 (hu)
HK (1) HK1034241A1 (hu)
HU (1) HUP0102472A3 (hu)
ID (1) ID26790A (hu)
IL (1) IL139697A (hu)
IS (1) IS2442B (hu)
NO (1) NO20006044L (hu)
NZ (1) NZ508222A (hu)
PL (1) PL194784B1 (hu)
PT (1) PT1084104E (hu)
RS (1) RS49984B (hu)
SK (1) SK18052000A3 (hu)
TR (1) TR200003539T2 (hu)
WO (1) WO1999062875A1 (hu)
ZA (1) ZA200006847B (hu)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60110902T2 (de) 2000-03-24 2006-04-27 Pharmacia Corp., Chicago Amidino-verbindung sowie salze davon verwendbar als hemmstoffe der stickstoffmonoxid-synthase
US7012098B2 (en) * 2001-03-23 2006-03-14 Pharmacia Corporation Inhibitors of inducible nitric oxide synthase for chemoprevention and treatment of cancers
JPWO2003022309A1 (ja) * 2001-09-10 2004-12-24 小野薬品工業株式会社 アレルギー疾患治療剤
US20030109522A1 (en) * 2001-09-24 2003-06-12 Manning Pamela T. Ophthalmologic treatment methods using selective iNOS inhibitors
WO2003097163A2 (en) * 2002-05-16 2003-11-27 Pharmacia Corporation Using a selective inos inhibitor for the treatment of respiratory diseases and conditions
JP2005532321A (ja) * 2002-05-16 2005-10-27 ファルマシア コーポレーション 呼吸器の疾患および状態の、選択的ｉＮＯＳ阻害剤とＰＤＥ阻害剤による治療方法、ならびにそのための組成物
KR20050059051A (ko) * 2002-08-02 2005-06-17 파마시아 코포레이션 위장 증상의 치료 및 예방 방법
AU2003278565A1 (en) * 2002-10-25 2004-05-13 Yissum Research Development Company Of The Hebrew University Of Jerusalem Steroid compounds comprising superoxide dismutase mimic groups and nitric oxide donor groups, and their use in the preparation of medicaments
US20060166894A1 (en) * 2002-11-29 2006-07-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and no-donor activity
TWI328009B (en) 2003-05-21 2010-08-01 Glaxo Group Ltd Quinoline derivatives as phosphodiesterase inhibitors
GB0316212D0 (en) * 2003-07-10 2003-08-13 Glaxo Group Ltd Novel compounds
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
WO2005025620A2 (en) * 2003-08-13 2005-03-24 Pharmacia Corporation Combination therapy with inhibitors of inducible nitric oxide synthase and alkylating agents
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
ATE517908T1 (de) 2005-01-10 2011-08-15 Glaxo Group Ltd Androstan-17-alpha-carbonat-derivate zur verwendung bei der behandlung allergischer und entzündlicher zustände
AR053346A1 (es) 2005-03-25 2007-05-02 Glaxo Group Ltd Compuesto derivado de 8h -pirido (2,3-d) pirimidin -7 ona 2,4,8- trisustituida composicion farmaceutica y uso para preparar una composicion para tratamiento y profilxis de una enfermedad mediada por la quinasa csbp/ rk/p38
TW200724142A (en) 2005-03-25 2007-07-01 Glaxo Group Ltd Novel compounds
JPWO2007000884A1 (ja) * 2005-06-29 2009-01-22 国立大学法人金沢大学 骨・関節疾患の予防・治療剤およびそのスクリーニング方法
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
TW200730498A (en) 2005-12-20 2007-08-16 Glaxo Group Ltd Compounds
BRPI0710240A2 (pt) 2006-04-20 2011-08-09 Glaxo Group Ltd composto, uso de um composto, método para o tratamento de um paciente humano ou animal com uma condição ou doença, composição farmacêutica, combinação, e, processo para a preparação de um composto
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
US8003663B2 (en) 2006-08-01 2011-08-23 Glaxo Group Limited Pyrazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors
WO2008147445A2 (en) * 2006-11-09 2008-12-04 University Of Maryland, Baltimore Use of 5,6-dimethylxanthenone-4-acetic acid as an antimicrobial agent
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
US8765743B2 (en) 2008-06-05 2014-07-01 Glaxosmithkline Intellectual Property Development Limited Compounds
JP5502858B2 (ja) 2008-06-05 2014-05-28 グラクソ グループ リミテッド Ｐｉ３キナーゼの阻害剤として有用な４−カルボキサミドインダゾール誘導体
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
US8354539B2 (en) 2009-03-10 2013-01-15 Glaxo Group Limited Indole derivatives as IKK2 inhibitors
JP2012520845A (ja) 2009-03-17 2012-09-10 グラクソ グループ リミテッド Ｉｔｋ阻害剤として使用されるピリミジン誘導体
WO2010107957A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010107955A2 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF BTB AND CNC HOMOLOGY 1, BASIC LEUCINE ZIPPER TRANSCRIPTION FACTOR 1 (BACH 1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) SEQUENCE LISTING
US20120016011A1 (en) 2009-03-19 2012-01-19 Merck Sharp & Dohme Corp. RNA Interference Mediated Inhibition of Connective Tissue Growth Factor (CTGF) Gene Expression Using Short Interfering Nucleic Acid (siNA)
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
KR20110138223A (ko) 2009-03-27 2011-12-26 머크 샤프 앤드 돔 코포레이션 짧은 간섭 핵산 (ｓｉＮＡ)을 사용한 세포간 부착 분자 1 (ＩＣＡＭ-1) 유전자 발현의 ＲＮＡ 간섭 매개 억제
EP2411019A2 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111490A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111464A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111468A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF THE NERVE GROWTH FACTOR BETA CHAIN (NGFß) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (SINA)
WO2010122088A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
WO2010122089A1 (en) 2009-04-24 2010-10-28 Glaxo Group Limited N-pyrazolyl carboxamides as crac channel inhibitors
MA33304B1 (fr) 2009-04-30 2012-05-02 Glaxo Group Ltd Indazoles substitués par oxazole comme inhibiteurs de pi3-kinase
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
US20120245171A1 (en) 2009-12-03 2012-09-27 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of pi3 kinases
JP2013512880A (ja) 2009-12-03 2013-04-18 グラクソ グループ リミテッド Ｐｉ３−キナーゼ阻害剤としてのインダゾール誘導体
WO2011084316A2 (en) 2009-12-16 2011-07-14 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
TWI375671B (en) * 2010-03-01 2012-11-01 Univ China Medical Pharmaceutical compositions containing brazilin for inhibiting expression of cytokines of t helper cell type ii and/or inhibiting expression of chemokines and uses of the same
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
JP5965402B2 (ja) 2010-09-08 2016-08-03 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｎ−［５−［４−（５−｛［（２ｒ，６ｓ）−２，６−ジメチル−４−モルホリニル］メチル｝−１，３−オキサゾール−２−イル）−１ｈ−インダゾール−６−イル］−２−（メチルオキシ）−３−ピリジニル］メタンスルホンアミドの多形体および塩
EP2613781B1 (en) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
US9149462B2 (en) 2010-10-21 2015-10-06 Glaxo Group Limited Pyrazole compounds acting against allergic, inflammatory and immune disorders
EP2630126B1 (en) 2010-10-21 2015-01-07 Glaxo Group Limited Pyrazole compounds acting against allergic, immune and inflammatory conditions
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
EP3046921A4 (en) 2013-09-22 2017-02-22 Calitor Sciences, LLC Substituted aminopyrimidine compounds and methods of use
WO2015148869A1 (en) 2014-03-28 2015-10-01 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
PE20170185A1 (es) 2014-05-12 2017-04-01 Glaxosmithkline Intellectual Property (No 2) Ltd Composiciones farmaceuticas para tratar enfermedades infecciosas
EP3347097B1 (en) 2015-09-11 2021-02-24 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora
JP7254076B2 (ja) 2017-11-19 2023-04-07 サンシャイン・レイク・ファーマ・カンパニー・リミテッド 置換ヘテロアリール化合物及び使用方法
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
JP2023519585A (ja) 2020-03-26 2023-05-11 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ウイルス感染を予防または治療するカテプシン阻害剤

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2049582A (en) 1931-11-04 1936-08-04 Rohm & Haas Amidines
US4085217A (en) 1964-01-29 1978-04-18 L'oreal Process and cosmetic compositions for the treatment of skin and scalp
US4085218A (en) 1975-10-30 1978-04-18 Sandoz Ltd. Elevating mood in geriatric patients
US4512979A (en) 1981-03-23 1985-04-23 Merck & Co., Inc. Dipeptides containing thialysine and related amino acids as antihypertensives
EP0068173B1 (en) 1981-06-05 1984-09-26 Merck & Co. Inc. Perhydro-1,4-thiazepin-5-one and perhydro-1,4-thiazocin-5-one derivatives, process for preparing and pharmceutical composition containing the same
US4594341A (en) 1982-04-06 1986-06-10 Merck & Co., Inc. Perhydro-1,4-thiazepin-5-one and perhydro-1,4-thiazocin-5-one derivatives as antihypertensives
FI832053L (fi) 1982-06-10 1983-12-11 Syntex Inc Nonapeptid- och dekapeptidanaloger av lhrh anvaendbara som lhrh-antagonister samt deras framstaellningsfoerfarande
DE3514450A1 (de) 1985-04-22 1986-10-23 Hoechst Ag, 6230 Frankfurt Verfahren zur herstellung von imidaten sowie neue arylsubstituierte imidate
US5028627A (en) 1989-09-13 1991-07-02 Cornell Research Foundation, Inc. Method of using arginine derivatives to inhibit systemic hypotension associated with nitric oxide production or endothelial derived relaxing factor
GB8929076D0 (en) 1989-12-22 1990-02-28 Scras Treatment of shock by blocking agents of edrf effect or formation
CA2036770C (en) 1990-02-26 2003-09-09 Jeffrey P. Whitten Inhibitors of nitric oxide biosynthesis
GB9127376D0 (en) 1991-12-24 1992-02-19 Wellcome Found Amidino derivatives
DE4310202A1 (de) 1992-03-30 1993-10-07 Ciba Geigy µ-Ketoimidoester als Stabilisatoren für chlorhaltige Polymerisate
US5281627A (en) 1992-05-28 1994-01-25 Cornell Research Foundation, Inc. Substituted arginines and substituted homoarginines and use thereof
US5585402A (en) 1992-12-23 1996-12-17 Glaxo Wellcome Inc. Nitric oxide synthase inhibitors
US5364881A (en) 1993-11-15 1994-11-15 The Medical College Of Wisconsin Research Foundation, Inc. S-alkyl-isothioureido-amino acids and use thereof
WO1995034534A1 (en) 1994-06-15 1995-12-21 The Wellcome Foundation Limited Enzyme inhibitors
FR2727111B1 (fr) 1994-11-21 1997-01-17 Hoechst Lab Nouveaux analogues soufres d'aminoacides, leur procede de preparation et leurs applications comme medicaments
MY117948A (en) * 1997-01-13 2004-08-30 Glaxo Group Ltd Nitride oxide synthase inhibitors.

Also Published As

Publication number Publication date
DK1084104T3 (da) 2003-10-27
DE69909625D1 (en) 2003-08-21
JP3839256B2 (ja) 2006-11-01
PT1084104E (pt) 2003-11-28
HUP0102472A2 (hu) 2002-03-28
ZA200006847B (en) 2001-11-22
HUP0102472A3 (en) 2002-12-28
AU4367199A (en) 1999-12-20
AP1382A (en) 2005-04-01
HK1034241A1 (en) 2001-10-19
US6355689B1 (en) 2002-03-12
RS49984B (sr) 2008-09-29
EA200001122A1 (ru) 2001-06-25
CA2333322A1 (en) 1999-12-09
EP1084104B1 (en) 2003-07-16
JP2002516901A (ja) 2002-06-11
IL139697A0 (en) 2002-02-10
NZ508222A (en) 2003-02-28
CA2333322C (en) 2008-01-22
KR20010043920A (ko) 2001-05-25
ATE245142T1 (de) 2003-08-15
WO1999062875A1 (en) 1999-12-09
GB9811599D0 (en) 1998-07-29
PL344368A1 (en) 2001-11-05
IS5723A (is) 2000-11-21
CZ297473B6 (cs) 2006-12-13
CN1303367A (zh) 2001-07-11
PL194784B1 (pl) 2007-07-31
ES2203147T3 (es) 2004-04-01
US6495606B1 (en) 2002-12-17
CN1218940C (zh) 2005-09-14
BR9910849A (pt) 2001-02-20
YU74600A (sh) 2002-12-10
EE04149B1 (et) 2003-10-15
SK18052000A3 (sk) 2001-06-11
NO20006044D0 (no) 2000-11-29
EE200000716A (et) 2002-04-15
CZ20004450A3 (en) 2001-05-16
AP2000001998A0 (en) 2000-12-31
NO20006044L (no) 2001-01-29
EA003026B1 (ru) 2002-12-26
AU757042B2 (en) 2003-01-30
IL139697A (en) 2005-12-18
IS2442B (is) 2008-11-15
TR200003539T2 (tr) 2001-06-21
DE69909625T2 (de) 2004-06-24
EP1084104A1 (en) 2001-03-21

Similar Documents

Publication Publication Date Title
ID26790A (id) Penghambat sinthase nitrat oksida
IS5618A (is) Bísýklískar hýdroxamsýru afleiður
DK0958277T3 (da) Inhibitorer for nitrogenmonoxidsyntase
ITMI981744A0 (it) Sali nitrati di farmaci
ATE243700T1 (de) Expandierte anionen enthaltende katalysatoraktivatoren
ID27092A (id) Pembuatan ftalat anhidrida
PT1077957E (pt) Derivados do acido oxi-iminoalcanoico
HUP0102719A3 (en) Nitrate salts of antihypertensive medicines
DE69937455D1 (de) Cyano-substituierte amidsalze
EE200100135A (et) EtO2C-CH2-(R)Cgl-Aze-Pab-OH kristalsed vormid
PT1062201E (pt) Derivados halogenados de amidino-aminoacidos uteis como inibidores da sintase do acido nitrico
DE69902486D1 (de) Zweiteiliges ritzelgetriebe
ID25901A (id) Proses pembuatan 4-aminometil-pirolidin-3-on terlindung
ID28032A (id) TRISIKLIK PIPERIDIN-Δ3-SEBAGAI ANTAGONIS-α2
EE9900474A (et) Amidiini derivaadid lämmastikoksiidi süntaasi inhibiitoritena
NO20016224D0 (no) Farmasöytisk blanding inneholdende sibutramin og orlistat
ATE218370T1 (de) Zubereitung mit verbesserter therapeutischer breite, enthaltend nukleotidsyntheseinhibitoren
ID24327A (id) Produksi senyawa-senyawa avermektin
NO20010637D0 (no) Fastfasesyntese av tio-oligosakkarider
PT1175417E (pt) Compostos substituidos de benzolactamas
FR2802296B1 (fr) Amelioration des projectiles composes
DE59900993D1 (de) Feste harnstoffverbindungen enthaltende wässrige elektrotauchlacke
TW530943U (en) Gelatine disc structure of electrophoresis slot
GB9919867D0 (en) Manufacture of water resistant ammonium nitrate explosives
KR980000950U (ko) 다양한 형태의 블럭을 이용한 조립완구